Building a Better Silver Bullet: Current Status and Perspectives of Non-Viral Vectors for mRNA Vaccines

In recent years, messenger RNA (mRNA) vaccines have exhibited great potential to replace conventional vaccines owing to their low risk of insertional mutagenesis, safety and efficacy, rapid and scalable production, and low-cost manufacturing. With the great achievements of chemical modification and sequence optimization methods of mRNA, the key to the success of mRNA vaccines is strictly dependent on safe and efficient gene vectors. Among various delivery platforms, non-viral mRNA vectors could represent perfect choices for future clinical translation regarding their safety, sufficient packaging capability, low immunogenicity, and versatility. In this review, the recent progress in the development of non-viral mRNA vectors is focused on. Various organic vectors including lipid nanoparticles (LNPs), polymers, peptides, and exosomes for efficient mRNA delivery are presented and summarized. Furthermore, the latest advances in clinical trials of mRNA vaccines are described. Finally, the current challenges and future possibilities for the clinical translation of these promising mRNA vectors are also discussed. This review has focused on up-to-date development of non-viral vectors for mRNA Vaccine. The advantages and disadvantages of various mRNA vector are commented and discussed. Meanwhile, the ongoing clinical trials of various mRNA vector are also summarized. The prospect of clinical transformation of various mRNA vectors are highlighted.image

Automated summary

In recent years, messenger RNA (mRNA) vaccines have shown great potential as replacements for conventional vaccines due to their low risk of mutagenesis, safety and effectiveness, rapid and scalable production, and low-cost manufacturing. Non-viral mRNA vectors are considered ideal choices for future clinical translation due to their safety, sufficient packaging capability, low immunogenicity, and versatility. This review focuses on the recent progress in the development of non-viral mRNA vectors, including lipid nanoparticles, polymers, peptides, and exosomes. It also discusses the latest advances in clinical trials of mRNA vaccines, as well as the current challenges and future possibilities for the clinical translation of these vectors.